



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

1 June 2021

Imagion Biosystems receives A\$2.6 million in R&D tax incentives

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that it has received its 2020 R&D tax incentive claim of \$2,612,159 from the Australian Taxation Office.

This is higher than the \$2,197,028 received in respect of the 2019 claim and reflects increased R&D spend in 2020 as the Company undertook preparatory activities towards the first-in-human trial of its MagSense® imaging technology in HER2 positive breast cancer patients.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 401018828

Imagion Biosystems Limited

ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystems.com